Re:Cognition Health, a pioneering brain and mind clinic in the United Kingdom, today announced it will expand its international clinical trial services to the United States, with the first clinic located in Fairfax County. These services will focus on Alzheimer’s disease and dementia-related services. Dr. James Bicksel, a neurologist who also sits on the board of directors for the Alzheimer’s Association and is the medical director of the Inova Memory Center, will lead the clinical trial team.
“Opening a new Fairfax County-based location to conduct clinical studies for Alzheimer’s and dementia is a very positive step for the future in fighting these diseases,” Bicksel said. “Our Virginia patients will have the opportunity to be involved in clinical trials of the next generation of emerging medications while also receiving outstanding medical care by a team of cognitive experts. We are very much looking forward to making a difference to the lives of people in the Washington, DC area.”
“We are excited to expand Re:Cognition Health’s centers into the USA, allowing for the opportunity for more people to gain access to the most advanced treatments available worldwide,” said Dr. Emer MacSweeney, CEO and medical director of Re:Cognition Health. “We are especially pleased to offer Virginia and DC-area Alzheimer’s and dementia patients the very best care and access to these groundbreaking medications.”
Re:Cognition Health is a leading center for international final phase clinical trials and is changing the future for those with memory loss and other symptoms of cognitive impairment. With more than 140,000 people living with a diagnosis of mild cognitive impairment or dementia in Virginia, Re:Cognition Health aims to support individuals – via its new Fairfax County location – with memory loss and other symptoms of cognitive impairment through providing education, clinical excellence and access to the most advanced treatments available worldwide.
Re:Cognition Health expects to employ 25 people within three years and invest several million dollars at the Fairfax facility.
“We are honored that Re:Cognition Health chose Fairfax County for its first U.S. clinic and delighted to add this company to the growing health-science industry sector in Fairfax County,” said Gerald L. Gordon, Ph.D., president and CEO of the Fairfax County Economic Development Authority (FCEDA). “Re:Cognition Health will find an excellent workforce and many possible partners here, while residents of Fairfax County and the Washington area will have access to more clinical and treatment options because the company is here.”
Re:Cognition Health and the Fairfax County Economic Development Authority (FCEDA) made the announcement at the 2018 SelectUSA Summit presented by the U.S. Department of Commerce to promote foreign direct investment in the United States. The FCEDA is exhibiting at the SelectUSA Summit as part of its longtime effort to promote Fairfax County as a location for foreign-owned companies that want to locate and expand in the U.S. As part of its international outreach program, the FCEDA has had a permanent representative in the London area since 1998 to work with U.K. companies that are interested in locating or expanding in the U.S. market.
Antony Phillipson, UK’s Trade Commissioner for North America, said, “Re:Cognition, founded by an American and a Brit, is an example of the innovative research collaborations between our countries that is advancing diagnosis and treatment of people with cognitive impairment, such as Alzheimer’s. This UK company’s new investment of $15 million into the US will start with a project in Virginia which could help the more than 140,000 people diagnosed with dementia in the state.”
The Washington, D.C., area, which includes Fairfax County, is the third-largest metropolitan area in the U.S. in health-care spending, with per-person spending that is 17 percent above the national average. In Fairfax, a cluster of life sciences companies drawn by region-wide workforce of 65,000 skilled life-sciences professionals, work in research and development, precision medicine, pharmaceuticals and bio-defense supported by a network of health-related IT companies specializing in clinical integration and data analytics.